Navigation Links
Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors

SAN DIEGO, Feb. 8 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has appointed William H. Rastetter Ph.D. to its Board of Directors effective immediately. He is the current Chairman and Chief Executive Officer of Receptos, Inc., and former Executive Chairman of Biogen Idec, Inc.

"We are very pleased to welcome Bill Rastetter to our Board of Directors," said Joseph A. Mollica, Ph.D., Chairman of the Board of Neurocrine Biosciences.  "The company is very fortunate to have someone with Bill's experience and proven track record in the biotech industry. He will be a valuable resource to Neurocrine as the Company moves forward."

Dr. Rastetter is currently the Chairman and Chief Executive Officer of Receptos, a privately-held drug discovery and development company which utilizes pioneering G protein-coupled receptor (GPCR) technology, including 3-dimensional structure determination of these membrane bound proteins, to facilitate information-driven drug design for developing best- and first-in-class drugs. He is also currently the Chairman of the Board of Directors of Illumina, Inc., and is a partner in the venture capital firm Venrock.

Dr. Rastetter retired as the Executive Chairman of Biogen Idec Inc., a biopharmaceutical company, at the end of 2005 and had served in that position since the November 2003 merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation. He served as Chief Executive Officer of IDEC Pharmaceuticals from December 1986 through November 2003 and as chairman of the Board of Directors from May 1996 to November 2003. Additionally, he served as President of IDEC Pharmaceuticals from 1986 to 2002 and as Chief Financial Officer from 1988 to 1993. From 1982 to 1986 Dr. Rastetter served in various positions at Genentech, Inc., a biotechnology company, and prior to Genentech he was an associate professor at the Massachusetts Institute of Technology.

Rastetter earned a Ph.D. from Harvard University in 1975.  He also holds a Masters of Arts in Chemistry from Harvard University and a Bachelor of Science degree in Chemistry from Massachusetts Institute of Technology.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at

SOURCE Neurocrine Biosciences, Inc.



SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
2. Neurocrine Biosciences Amends Corporate Headquarters Lease
3. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
4. Neurocrine Biosciences Secures Committed Equity Financing Facility
5. Neurocrine Biosciences Reports Second Quarter 2009 Results
6. Webcast Alert: Neurocrine Biosciences Announces 2nd Quarter 2009 Earnings Results
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results
8. Neurocrine Biosciences to Present at the 8th Annual Needham Life Sciences Conference
9. Neurocrine Biosciences to Present at the Deutsche Bank 34th Annual Health Care Conference
10. Neurocrine Biosciences Reports First Quarter 2009 Results
11. Neurocrine Announces Work Force Restructuring
Post Your Comments:
(Date:11/28/2015)... ... November 28, 2015 , ... • Jeon Jin Bio ... porcine and rodent control solutions , Bird ... oil, works across all sensory modalities including visual, smell, taste and touch, enabling safe, ...
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... 2015 --> ... - 2020 report analyzes that automating biobanking workflow ... in long-term samples, minimizing manual errors, improving the ... manual errors such as mislabeling or inaccurate sample ... plays a vital role in blood fractionation, DNA ...
(Date:11/25/2015)... , November 25, 2015 ... cat and human plaque and pave the way for more ... problems in cats     --> ... most commonly diagnosed health problems in cats, yet relatively little ... now. Two collaborative studies have been conducted by researchers from ...
Breaking Biology Technology:
(Date:11/19/2015)... YORK , Nov. 19, 2015  Although some ... market is dominated by a few companies, according to ... companies own 51% of the market share of the ... The World Market for Molecular Diagnostic s ... "The market is still controlled by one company ...
(Date:11/17/2015)...  Vigilant Solutions announces today that Mr. Dick ... --> --> Mr. ... partnership at TPG Capital, one of the largest global ... in revenue.  He founded and led TPG,s Operating Group, ... from 1997 to 2013.  In his first role, he ...
(Date:11/12/2015)... 2015   Growing need for low-cost, easy ... been paving the way for use of biochemical ... analytes in clinical, agricultural, environmental, food and defense ... in medical applications, however, their adoption is increasing ... continuous emphasis on improving product quality and growing ...
Breaking Biology News(10 mins):